Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation announced that its CEO, Ben Zeskind, will participate in a virtual healthcare conference presentation. The company highlighted its lead drug candidate, atebimetinib, entering a pivotal Phase 3 trial in pancreatic cancer expected to begin dosing mid-2026. This trial targets improved survival in MAPK pathway-driven tumors, pot…